Pfizer (PFE)

The most recent research report on the "Addiction Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally.

The most recent research report on the "Rituxan (rituximab) Drug Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore

The most recent research report on the "Drugs for Oral Mucositis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Explore how two quantum innovators stack up on customer reach, financial health, and risk as they race for commercial leadership in a fast-evolving sector.

These three dividend stocks combine strong yields with resilient businesses.

The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies.

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

The pharma giant is taking steps to expand its portfolio.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.

Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.

The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Honeywell is spinning off its aerospace segment, which could trigger a shake-up in the Dow Jones Industrial Average this summer.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell shor...

The market appears to be short-sighted.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

These stocks could look like steals in a few years.

Honeywell was added to the Dow for its tech focus and diversification across different end markets.